Table 2.

Disease-fee survival at three and five years for stage III colon cancer treated with oxaliplatin-based chemotherapy according to recently reported studies

Trial	Regimen (treatment group)	DFS at three years (%)	DFS at five years (%)
MOSAIC [1, 2••]	FOLFOX4 (experimental)	72.2	66.4
NSABP C-07 [3, 4•]	FLOX (experimental)	NE	64.4
NO16968 [5••, 6]	XELOX (experimental)	70.9	66.1
NSABP C-08 [13•]	mFOLFOX6 (control)	72	NE
AVANT [17]	FOLFOX4 (control)	76	NE
NCCTG [16]	mFOLFOX6 (control)	75	NE
PETACC8 Intergroup [18]	FOLFOX4 (control)	78	NE

NE, not evaluated